Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor)\, to be used in combination with ivacaftor (KALYDECO®)\, for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene